Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,964 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test product Clear all
Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

NCT04108858
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Copanlisib, Pertuzumab, Trastuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Not applicable Interventional

A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives

NCT01935440
View directory record Official record
Conditions
HIV
Interventions
Prevention & Testing, Prevention & Testing Control
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

NCT03023891
View directory record Official record
Conditions
Glucocorticoids Toxicity, Glucose Intolerance
Interventions
Prednisone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238
View directory record Official record
Conditions
Healthy Subjects
Interventions
Recombinant human erythropoietin alfa (drug), Aspirin (drug), Clopidogrel (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2006 · Synced Sep 3, 2026, 2:29 AM EDT
Active, not recruiting No phase listed Observational

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

NCT05983276
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Decitabine, Carboplatin, Paclitaxel, Selinexor
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Not applicable Interventional

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

NCT04337515
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease
Interventions
CliniMacs®
Device
Lead sponsor
Christopher Dvorak
Other
Eligibility
Up to 30 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

NCT00569868
View directory record Official record
Conditions
MULTIPLE MYELOMA
Interventions
Velcade
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 3, 2026, 2:29 AM EDT
Completed No phase listed Observational

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

NCT03605810
View directory record Official record
Conditions
Renal Function
Interventions
No Intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,132,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 3, 2026, 2:29 AM EDT
Enrolling by invitation No phase listed Observational

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07520279
View directory record Official record
Conditions
Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions
Xpert Tropical Fever test
Diagnostic Test
Lead sponsor
Cepheid
Industry
Eligibility
14 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

NCT07305779
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-380135, Quinidine Gluconate
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Tacrolimus in Healthy Volunteers

NCT04725682
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tacrolimus
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 59 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

NCT00538668
View directory record Official record
Conditions
Prostate Cancer
Interventions
117Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 3, 2026, 2:29 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Developing a Mobile Method to Measure THC-induced Impairment

NCT03804840
View directory record Official record
Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

NCT00933868
View directory record Official record
Conditions
Stroke
Interventions
Magnesium Chloride, Placebo
Drug
Lead sponsor
Relox Medical, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Sep 3, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Reported Outcomes for Opioid Use Disorder

NCT03985163
View directory record Official record
Conditions
Opioid-use Disorder, Overdose of Opiate, Patient Participation
Interventions
Patient Reported Outcomes Electronic Survey
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Recombinant human erythropoietin alfa (drug), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

NCT00975650
View directory record Official record
Conditions
Hypogonadism
Interventions
Nasobol®, Androderm® (Positive Control)
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Cockroach Immunotherapy in Children and Adolescents

NCT03541187
View directory record Official record
Conditions
Persistent Asthma
Interventions
German cockroach allergenic extract, Placebo for German cockroach allergenic extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT03410693
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Rogaratinib (BAY1163877), Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 3, 2026, 2:29 AM EDT